# Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A

> **NCT02634723** · — · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 21 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **BIOLOGICAL:** Octocog alfa (recombinant human coagulation factor VIII)

## Key facts

- **NCT ID:** NCT02634723
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-23
- **Primary completion:** 2016-06-30
- **Final completion:** 2016-06-30
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2021-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02634723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02634723, "Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02634723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*